肝癌肝动脉化疗栓塞术后发生感染影响因素分析  

The influencing factors for the infection occurring after TACE in patients with liver cancer

作　　者：姜敏霞[1] 陈旭高[1] 姚红响[1] 

机构地区：[1]浙江省丽水市人民医院放射科,323000

出　　处：《介入放射学杂志》2018年第2期133-136,共4页Journal of Interventional Radiology

基　　金：浙江省丽水市科技计划项目(2012ZC039)

摘　　要：目的探讨肝癌患者行TACE术后感染的发生情况及影响因素。方法回顾性调查2016年1-12月行TACE手术的病例,分析TACE术后感染发生的可能危险因素,并对其进行单因素分析和Logistic多因素回归分析,并将TACE术后发生感染的相关因素进行风险分层,分为极高危、高危、中危和低危。结果 386例有效TACE手术病例发生术后感染17例,发生率为4.4%。其中腹水、肝胆切除手术史或术前有肝癌破裂出血、肝脓肿史或既往TACE术后感染史是TACE术后感染的极高危因素,前血清总蛋白值<60 g/L是高危因素,门静脉或腔静脉癌栓是中危因素。结论腹水、肝胆手术史或术前有肝癌破裂出血、肝脓肿史或既往TACE术后感染史与TACE术后发生感染显著相关。Objective To investigate the incidence and influencing factors of postoperative infection in patients with hepatocellular carcinoma（HCC） after transcatheter arterial chemoembolization（TACE）.Methods A retrospective study was conducted on the HCC patients who received TACE during the period from January 2016 to December 2016. The possible risk factors that might induce postoperative infection after TACE were evaluated by using univariate analysis and multivariate logistic regression analysis. The risk factors were further stratified into very high risk factors, high risk factors, moderate risk factors and low risk factors. Results Among 386 HCC patients who showed effective response to TACE, postoperative infection occurred in 17 patients, the incidence rate was 4.4%. Ascites, history of hepatobiliary resection surgery or preoperative liver cancer rupture with bleeding, history of liver abscess or previous postoperative infection after TACE were the very high risk factors of infection after TACE. Preoperative serum total protein value 60 g/L was a high risk factor. The presence of tumor thrombus in portal vein or in vena cava was a moderate risk factor. Conclusion Ascites, previous hepatobiliary surgery, preoperative liver cancer rupture with bleeding, history of liver abscess and history of infection after TACE are significantly correlated with the occurrence of infection after TACE.

关 键 词：肝肿瘤 肝动脉化疗栓塞术 术后感染 LOGISTIC回归分析 

分 类 号：R735.7[医药卫生—肿瘤]